<DOC>
	<DOCNO>NCT02859324</DOCNO>
	<brief_summary>CC-122-HCC-002 Phase 1/2 dose escalation expansion clinical study CC-122 combination nivolumab subject unresectable hepatocellular carcinoma ( HCC ) progress intolerant 2 previous systemic therapy unresectable HCC , naïve systemic therapy .</brief_summary>
	<brief_title>A Safety Efficacy Study CC-122 Combination With Nivolumab Subjects With Unresectable Hepatocellular Carcinoma ( HCC )</brief_title>
	<detailed_description>Subjects receive either none 2 previous systemic therapy . The dose escalation part study explore 1 dose level CC-122 combination nivolumab use modify dose escalation ( 3+3 ) design , follow expansion part recommend Phase 2 dose ( RP2D ) define . A modify 3+3 dose escalation design use identify initial toxicity combination . Up six subject concurrently enrol dose level . Decisions dose level enroll new subject base number subject enrol evaluable , number subject experience DLTs , number subject enrol yet evaluable toxicity current cohort time new subject entry .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Nivolumab</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Subjects must satisfy follow criterion enrol study : Subject ≥ 18 year age time sign informed consent form ( ICF ) Subject confirm pathologic diagnosis Hepatocellular carcinoma ( HCC ) accord American Association Study Liver Diseases ( AASLD ) Guidelines . Subjects progress intolerant 2 previous systemic therapy unresectable HCC , naïve systemic therapy . Subject least one measurable lesion accord RECIST 1.1 . Subject life expectancy ≥ 12 week Subject Eastern Cooperative Oncology Group Performance Status ( ECOG PS ) 0 1 Subject adequate hematologic function adequate hepatic function screen The presence follow exclude subject enrollment : Subject receive 2 previous systemic therapy Hepatocellular carcinoma ( HCC ) . Subject receive previous treatment antiPD1 ( Programmed death 1 ) antiPDL1 ( PD1 ligand receptor ) antibody</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>CC-122</keyword>
	<keyword>Nivolumab</keyword>
	<keyword>Hepatocellular Carcinoma</keyword>
	<keyword>Phase 1/2</keyword>
	<keyword>Safety</keyword>
</DOC>